schliessen

Filtern

 

Bibliotheken

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial

The RITUXVAS trial reported similar remission induction rates and safety between rituximab and cyclophosphamide based regimens for antineutrophil cytoplasm antibody (ANCA)-associated vasculitis at 12 months; however, immunosuppression maintenance requirements and longer-term outcomes after rituximab... Full description

Journal Title: Annals of the Rheumatic Diseases 4 March 2015
Main Author: Jones, Rachel B
Other Authors: Furuta, Shunsuke , Cohen Tervaert, Jan Willem , Hauser, Thomas , Luqmani, Raashid , Morgan, Matthew D , Peh, Chen Au , Savage, Caroline O , Segelmark, Marten , Tesar, Vladimir , van Paassen, Pieter , Walsh, Michael , Westman, Kerstin , Jayne, David RW
Format: Electronic Article Electronic Article
Language: English
Subjects:
Publisher: BMJ Publishing Group Ltd and European League Against Rheumatism
ID: ISSN: 0003-4967 ; E-ISSN: 1468-2060 ; DOI: 10.1136/annrheumdis-2014-206404 ; PMID: 25739829
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: bmj_journals10.1136/annrheumdis-2014-206404
title: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial
format: Article
creator:
  • Jones, Rachel B
  • Furuta, Shunsuke
  • Cohen Tervaert, Jan Willem
  • Hauser, Thomas
  • Luqmani, Raashid
  • Morgan, Matthew D
  • Peh, Chen Au
  • Savage, Caroline O
  • Segelmark, Marten
  • Tesar, Vladimir
  • van Paassen, Pieter
  • Walsh, Michael
  • Westman, Kerstin
  • Jayne, David RW
subjects:
  • B Cells
  • Cyclophosphamide
  • Granulomatosis With Polyangiitis
  • Systemic Vasculitis
  • Treatment
ispartof: Annals of the Rheumatic Diseases, 4 March 2015
description: The RITUXVAS trial reported similar remission induction rates and safety between rituximab and cyclophosphamide based regimens for antineutrophil cytoplasm antibody (ANCA)-associated vasculitis at 12 months; however, immunosuppression maintenance requirements and longer-term outcomes after rituximab in ANCA-associated renal vasculitis are unknown.
language: eng
source:
identifier: ISSN: 0003-4967 ; E-ISSN: 1468-2060 ; DOI: 10.1136/annrheumdis-2014-206404 ; PMID: 25739829
fulltext: fulltext
issn:
  • 00034967
  • 14682060
  • 0003-4967
  • 1468-2060
url: Link


@attributes
ID1242951988
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10.1136/annrheumdis-2014-206404
sourceidbmj_journals
recordidTN_bmj_journals10.1136/annrheumdis-2014-206404
sourcesystemPC
pqid1680179809
galeid414937729
display
typearticle
titleRituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial
creatorJones, Rachel B ; Furuta, Shunsuke ; Cohen Tervaert, Jan Willem ; Hauser, Thomas ; Luqmani, Raashid ; Morgan, Matthew D ; Peh, Chen Au ; Savage, Caroline O ; Segelmark, Marten ; Tesar, Vladimir ; van Paassen, Pieter ; Walsh, Michael ; Westman, Kerstin ; Jayne, David RW
publisherBMJ Publishing Group Ltd and European League Against Rheumatism
ispartofAnnals of the Rheumatic Diseases, 4 March 2015
identifier
subjectB Cells ; Cyclophosphamide ; Granulomatosis With Polyangiitis ; Systemic Vasculitis ; Treatment
descriptionThe RITUXVAS trial reported similar remission induction rates and safety between rituximab and cyclophosphamide based regimens for antineutrophil cytoplasm antibody (ANCA)-associated vasculitis at 12 months; however, immunosuppression maintenance requirements and longer-term outcomes after rituximab in ANCA-associated renal vasculitis are unknown.
languageeng
source
version9
lds50peer_reviewed
links
openurl$$Topenurl_article
linktorsrc$$Uhttp://ard.bmj.com/content/early/2015/03/03/annrheumdis-2014-206404.full.pdf$$EView_this_record_in_BMJ_Journals
openurlfulltext$$Topenurlfull_article
search
creatorcontrib
0Jones, Rachel B
1Furuta, Shunsuke
2Cohen Tervaert, Jan Willem
3Hauser, Thomas
4Luqmani, Raashid
5Morgan, Matthew D
6Peh, Chen Au
7Savage, Caroline O
8Segelmark, Marten
9Tesar, Vladimir
10van Paassen, Pieter
11Walsh, Michael
12Westman, Kerstin
13Jayne, David RW
titleRituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial
descriptionThe RITUXVAS trial reported similar remission induction rates and safety between rituximab and cyclophosphamide based regimens for antineutrophil cytoplasm antibody (ANCA)-associated vasculitis at 12 months; however, immunosuppression maintenance requirements and longer-term outcomes after rituximab in ANCA-associated renal vasculitis are unknown.
subject
0B Cells
1Cyclophosphamide
2Granulomatosis With Polyangiitis
3Systemic Vasculitis
4Treatment
general
0English
1BMJ Publishing Group Ltd and European League Against Rheumatism
2BMJ Journals (BMJ Publishing Group)
310.1136/annrheumdis-2014-206404
425739829
sourceidbmj_journals
recordidbmj_journals10.1136/annrheumdis-2014-206404
issn
000034967
114682060
20003-4967
31468-2060
rsrctypearticle
creationdate2015
addtitleAnnals of the Rheumatic Diseases
searchscopebmj
scopebmj
startdate20150304
enddate20150304
lsr30VSR-Enriched:[galeid, vol, pqid, pages, issue]
sort
titleRituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial
authorJones, Rachel B ; Furuta, Shunsuke ; Cohen Tervaert, Jan Willem ; Hauser, Thomas ; Luqmani, Raashid ; Morgan, Matthew D ; Peh, Chen Au ; Savage, Caroline O ; Segelmark, Marten ; Tesar, Vladimir ; van Paassen, Pieter ; Walsh, Michael ; Westman, Kerstin ; Jayne, David RW
creationdate20150304
lso0120150304
facets
frbrgroupid8569686245326350230
frbrtype5
languageeng
creationdate2015
topic
0B Cells
1Cyclophosphamide
2Granulomatosis With Polyangiitis
3Systemic Vasculitis
4Treatment
collectionBMJ Journals (BMJ Publishing Group)
creatorcontrib
0Jones, Rachel B
1Furuta, Shunsuke
2Cohen Tervaert, Jan Willem
3Hauser, Thomas
4Luqmani, Raashid
5Morgan, Matthew D
6Peh, Chen Au
7Savage, Caroline O
8Segelmark, Marten
9Tesar, Vladimir
10van Paassen, Pieter
11Walsh, Michael
12Westman, Kerstin
13Jayne, David RW
jtitleAnnals of the Rheumatic Diseases
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Jones
1Furuta
2Cohen Tervaert
3Hauser
4Luqmani
5Morgan
6Peh
7Savage
8Segelmark
9Tesar
10van Paassen
11Walsh
12Westman
13Jayne
aufirst
0Rachel B
1Shunsuke
2Jan Willem
3Thomas
4Raashid
5Matthew D
6Chen Au
7Caroline O
8Marten
9Vladimir
10Pieter
11Michael
12Kerstin
13David RW
auinitR
au
0Jones, Rachel B
1Furuta, Shunsuke
2Cohen Tervaert, Jan Willem
3Hauser, Thomas
4Luqmani, Raashid
5Morgan, Matthew D
6Peh, Chen Au
7Savage, Caroline O
8Segelmark, Marten
9Tesar, Vladimir
10van Paassen, Pieter
11Walsh, Michael
12Westman, Kerstin
13Jayne, David RW
atitleRituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial
jtitleAnnals of the Rheumatic Diseases
stitleAnn Rheum Dis
risdate20150304
issn
00003-4967
100034967
eissn
01468-2060
114682060
formatjournal
abstractThe RITUXVAS trial reported similar remission induction rates and safety between rituximab and cyclophosphamide based regimens for antineutrophil cytoplasm antibody (ANCA)-associated vasculitis at 12 months; however, immunosuppression maintenance requirements and longer-term outcomes after rituximab in ANCA-associated renal vasculitis are unknown.
pubBMJ Publishing Group Ltd and European League Against Rheumatism
doi10.1136/annrheumdis-2014-206404
urlhttp://ard.bmj.com/content/early/2015/03/03/annrheumdis-2014-206404.full.pdf
pmid25739829
volume74
pages1178-1182
issue6
date2015-03-04